Zevalin (Ibritumomab tiuxetan)

Zevalin (Ibritumomab tiuxetan) is a targeted cancer treatment used primarily for types of non-Hodgkin lymphoma. It combines a monoclonal antibody, which specifically binds to cancer cells, with a radioactive isotope. This allows it to deliver radiation directly to the tumor, minimizing damage to surrounding healthy tissue. The treatment helps destroy cancer cells and can be used after other therapies, like chemotherapy, to improve outcomes. Zevalin is usually administered through an injection and is part of a larger treatment plan monitored by healthcare professionals.